A+ A A-

Download article


Dikareva E.A., Velichinskaya O.G.
Dermatomyositis (clinical case)
Vitebsk State Order of Peoples’ Friendship Medical University, Vitebsk, Republic of Belarus

Vestnik VGMU. 2019;18(2):116-122.

At the beginning of the disease dermatomyositis is characterized by a different clinical pattern. This fact leads to the situation when patients begin to take different medical specialists advice, but do not go to a rheumatologist who deals with this pathology and is well aware of the nature of the course and various clinical manifestations of dermatomyositis.
This article describes the clinical case of primary idiopathic dermatomyositis in a woman aged 62 years. The female patient had typical clinical symptoms (progressive symmetric muscle weakness in the proximal parts of upper and lower extremities; myalgia; muscle tenderness on palpation; difficulty on making any movements; joint pain; heliotropic rash; the presence of Gottron syndrome in the area of the extensor surface of the finger joints; increased body temperature up to 39.0°C) and laboratory and instrumental changes (the increase in the level of creatine phosphokinase; the presence of typical changes during electroneuromyography; antibodies to Jo-1, the increase of the ESR up to 35 mm/h) that are characteristic of dermatomyositis. Duly made diagnosis allowed to promptly administer immunosuppression therapy, that enabled the stabilization of the patient’s condition and reduction of dermatomyositis activity.
Key words: dermatomyositis, arthralgia, myalgia, autoimmune disease, antibodies.


1. Beel AJ, Demos DS, Chung A, Liao C, Lui NS. Ground-glass opacity heralding invasive lung adenocarcinoma with prodromal dermatomyositis: a case report. J Cardiothorac Surg. 2018 Feb;13(1):20. doi:
2. Bernet LL, Lewis MA, Rieger KE, Casciola-Rosen L, Fiorentino DF. Ovoid palatal patch in dermatomyositis: a novel finding associated with anti-TIF1γ (p155) antibodies. JAMA Dermatol. 2016 Sep;152(9):1049-51. doi:
3. Orlova EV, Plieva LR, Pyatilova PM, Novosartyan MG. Dermatomyositis: clinical case and literature review. RMZh. 2017;(11):850-2. (In Russ.)
4. Cassius C, Le Buanec H, Bouaziz JD, Amode R. Biomarkers in adult dermatomyositis: tools to help the diagnosis and predict the clinical outcome. J Immunol Res. 2019 Jan;2019:9141420. doi:
5. Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of Dermatomyositis and Clinically Amyopathic Dermatomyositis: A Population-Based Study in Olmsted County, Minnesota. Arch Dermatol. 2010 Jan;146(1):26-30. doi:
6. Marvi U, Chung L, Fiorentino DF. Clinical presentation and evaluation of dermatomyositis. Indian J Dermatol. 2012 Sep;57(5):375-81. doi:
7. Buchbinder R, Hill CL. Malignancy in patients with inflammatory myopathy. Curr Rheumatol Rep. 2002 Oct;4(5):415-26.
8. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001 Jan;357(9250):96-100.
9. Reed AM, Ytterberg SR. Genetic and environmental risk factors for idiopathic inflammatory myopathies. Rheum Dis Clin North Am. 2002 Nov;28(4):891-916.
10. Sarkar K, Weinberg CR, Oddis CV, Medsger TA, Plotz PH, Reveille JD, et al. Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined groups. Arthritis Rheum. 2005 Aug;52(8):2433-8. doi:
11. Nagaraju K, Lundberg IE. Polymyositis and dermatomyositis: pathophysiology. Rheum Dis Clin North Am. 2011 May;37(2):159-71. doi:
12. Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford). 2009 Jun;48(6):607-12. doi:
13. Mierau R, Dick T, Bartz-Bazzanella P, Keller E, Albert ED, Genth E. Strong association of dermatomyositis-specific Mi-2 autoantibodies with a tryptophan at position 9 of the HLA-DR beta chain. Arthritis Rheum. 1996 May;39(5):868-76.
14. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991 Nov;70(6):360-74.
15. Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015 Apr;372(18):1734-47. doi:
16. Trallero-Araguás E, Rodrigo-Pendás JÁ, Selva-O'Callaghan A, Martínez-Gómez X, Bosch X, Labrador-Horrillo M, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012 Feb;64(2):523-32. doi:
17. Tanimoto K, Nakano K, Kano S, Mori S, Ueki H, Nishitani H, et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol. 1995 Apr;22(4):668-74.
18. Zykova AS, Novikov PI, Moiseev SV. Adult dermatomyositis: new diagnostic criteria and therapy perspectives. Klin Farmakologiia Terapiia. 2017;26(2):83-92. (In Russ.)
19. Matveeva TV, Egorova KE, Mullayanova RF. Dermatomyositis in the practice of a neurologist in the emergency neurology department. Kazan Med Zhurn. 2017;98(2):267-71. (In Russ.)

Information about authors:
Dikareva E.A .– Candidate of Medical Sciences, associate professor of the General Practitioner Chair with the course of Outpatient Therapy, Vitebsk State Order of Peoples’ Friendship Medical University;
Velichinskaya O.G. – Candidate of Medical Sciences, associate professor of the General Practitioner Chair with the course of Outpatient Therapy, Vitebsk State Order of Peoples’ Friendship Medical University.

Correspondence address: Republic of Belarus, 210009, Vitebsk, 27 Frunze ave., Vitebsk State Order of Peoples’ Friendship Medical University, General Practitioner Chair with the course of Outpatient Therapy. E-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Elena A. Dikareva.

Поиск по сайту